Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
Enter Symbol
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
30M
Market Cap:
$0.16B
Avg Volume:
185188
P/E Ratio:
-0.010
PEG Ratio:
-0.010
1m
3m
6m
1y
2y
Opinion and Analysis
Supernus Pharma (SUPN) Receives FDA Approval For Oxtellar XR To Treat Epilepsy
Oct 22, 2012 08:04 AM |
The FDA Will Change Supernus Pharmaceuticals (SUPN) Stock Price - Soon
Oct 18, 2012 02:24 PM |
NVS
iStock Picks: The Courage To Look Back
Jul 18, 2012 06:08 PM |
ARNA
,
OSUR
,
ROSG
More Articles on SUPN..
Press Releases
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results
May 13, 2013 04:01 PM |
Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast
May 06, 2013 04:30 PM |
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019
May 06, 2013 08:01 AM |
More Press Releases on SUPN..
SEC Filings
Form 4 SUPERNUS PHARMACEUTICALS For: Mar 14 Filed by: PATRICK GREGORY S (10K)
Mar 15, 2013 04:35 PM
Form 4 SUPERNUS PHARMACEUTICALS For: Feb 08 Filed by: Bhatt Padmanabh P. (10K)
Feb 12, 2013 04:05 PM
Form 4 SUPERNUS PHARMACEUTICALS For: Feb 05 Filed by: Vaughn Victor (10K)
Feb 07, 2013 07:47 PM
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
SUPN
Compare to S&P
YTD
-26.08 %
-32.22 %
4 Weeks
-8.93 %
-8.84 %
12 Weeks
-29.14 %
-31.53 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
7.27 %
EPS Growth in Last Year:
-0.01 %
Sales Growth in Last Quarter:
1,097.80 %
Sales Growth in Last Quarter:
2,625.00 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##